Revolution Medicines (RVMDW) Return on Capital Employed (2020 - 2026)
Revolution Medicines (RVMDW) posted quarterly Return on Capital Employed of 68.84% for Q1 2026, down 3457.0% year-over-year from 2.05% in Q1 2025, and down 17.19% quarter-over-quarter from 58.74% in Q4 2025.
Revolution Medicines (RVMDW) Return on Capital Employed (2020 - 2026) Analysis & Trends
Revolution Medicines' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 68.84% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3457.0% year-over-year to 68.84%; the TTM figure through Mar 2026 stood at 68.84% (down 3457.0% YoY), while the FY2025 annual figure was 54.59%, down 2246.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 68.84%, down from 58.74% in the prior quarter.
- The five-year high for Return on Capital Employed was 29.23% in Q1 2024, with the low at 81.79% in Q3 2024.
- The 5-year median for Return on Capital Employed is 38.03% (2022), against an average of 43.88%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 4269 bps in 2024, then soared 3230 bps in 2025.
- Revolution Medicines' Return on Capital Employed stood at 34.12% in 2022, then fell by 4 bps to 35.33% in 2023, then gained by 2 bps to 34.53% in 2024, then slumped by 70 bps to 58.74% in 2025, then dropped by 17 bps to 68.84% in 2026.
- Business Quant data shows RVMDW's Return on Capital Employed at 68.84% in Q1 2026, 58.74% in Q4 2025, and 49.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Revolution Medicines | 2.45 Bn | 2.45 Bn | - | -55.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.45% |
| Mar 31, 2026 | -68.84% |
| Dec 31, 2025 | -58.74% |
| Sep 30, 2025 | -49.50% |
| Jun 30, 2025 | -40.56% |
| Mar 31, 2025 | -34.27% |
| Dec 31, 2024 | -34.53% |
| Sep 30, 2024 | -81.79% |
| Jun 30, 2024 | -68.51% |
| Mar 31, 2024 | -29.23% |
| Dec 31, 2023 | -35.33% |
| Sep 30, 2023 | -39.10% |
| Jun 30, 2023 | -32.37% |
| Mar 31, 2023 | -31.02% |
| Dec 31, 2022 | -34.12% |
| Sep 30, 2022 | -38.03% |
| Jun 30, 2022 | -38.05% |
| Mar 31, 2022 | -31.94% |
| Dec 31, 2021 | -27.81% |
| Sep 30, 2021 | -24.08% |